Prior Authorization for GLP-1 Weight Loss Drugs: How to Get Approved for Wegovy, Zepbound, Ozempic, and Mounjaro

What Is Prior Authorization and Why Do GLP-1 Drugs Always Require It?

Prior authorization is an insurer's requirement that a prescriber obtain written approval before a drug will be covered. GLP-1 medications face near-universal PA requirements because their list prices exceed $900 per month and insurers classify them as specialty-tier drugs. PA exists to confirm that a patient meets clinical criteria before the plan pays.

These drugs are not cheap to manufacture. Novo Nordisk's Wegovy carries a wholesale acquisition cost of approximately $1,349 per month, and Eli Lilly's Zepbound lists at approximately $1,060 per month. Those prices reflect long clinical development timelines: STEP-1 (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [1], and SURMOUNT-1 (N=2,539) demonstrated that tirzepatide 15 mg achieved 20.9% mean body-weight reduction at 72 weeks versus 3.1% with placebo [2]. Insurers treat these efficacy data as confirmation that the drugs work, but the cost makes gatekeeping almost inevitable.

Most commercial plans, Medicare Advantage plans, and Medicaid programs use nearly identical PA criteria sets, modeled on FDA labeling. Knowing that criteria in advance is the fastest way to get a clean first-pass approval.

Standard Prior Authorization Criteria for Wegovy and Zepbound (Weight Loss Indications)

Most payers require all four of the following before approving Wegovy or Zepbound for chronic weight management.

1. BMI threshold. The FDA-approved Wegovy label specifies use in adults with an initial BMI of 30 kg/m² or higher, or 27 kg/m² or higher in the presence of at least one weight-related comorbidity [3]. Zepbound's FDA label mirrors this language [4]. Insurers copy this threshold almost verbatim into their PA criteria.

2. Documented comorbidity (if BMI is 27 to 29.9). Qualifying comorbidities include type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or established cardiovascular disease. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in non-diabetic adults with obesity and pre-existing cardiovascular disease, which is the clinical rationale for the cardiovascular indication now recognized by some payers [5].

3. Prior non-pharmacologic attempts. Nearly every payer requires documentation of a structured diet and exercise program lasting at least 3 to 6 months that produced inadequate weight loss. This means chart notes, not a patient's verbal history. A registered dietitian encounter note or a formal behavioral program discharge summary satisfies most plans.

4. Absence of contraindications. Wegovy and Zepbound carry a boxed warning about thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [3][4]. Insurers require that the prescriber attest to these exclusions.

The AACE/ACE Obesity Clinical Practice Guidelines recommend pharmacotherapy as an adjunct to lifestyle modification when BMI meets these thresholds and behavioral treatment alone has been insufficient [6]. Citing this guideline in the PA letter strengthens the medical necessity argument.

How Prior Authorization Differs for Ozempic and Mounjaro (Diabetes Indications)

Ozempic (semaglutide 1 mg and 2 mg) and Mounjaro (tirzepatide 2.5 to 15 mg) carry FDA approval for type 2 diabetes, not chronic weight management. PA criteria for the diabetes indication are different and often easier to satisfy.

For Ozempic, most plans require a confirmed type 2 diabetes diagnosis (ICD-10 code E11.x), an HbA1c above a payer-specific threshold (commonly 7.5% to 8.0%), and a trial of metformin unless metformin is contraindicated or not tolerated. STEP-2 (N=1,210) showed semaglutide 1 mg reduced HbA1c by 1.6 percentage points at 68 weeks in patients with type 2 diabetes and overweight or obesity [7]. That efficacy supports the clinical necessity argument clearly.

For Mounjaro, the same general diabetes criteria apply. SURMOUNT-2 (N=938) showed tirzepatide 15 mg reduced HbA1c by 2.58 percentage points and body weight by 14.7% at 72 weeks in adults with type 2 diabetes and obesity [8]. Some payers also require a documented cardiovascular risk assessment or prior GLP-1 failure before approving tirzepatide over the lower-cost semaglutide option.

One trap many patients fall into: getting Ozempic approved for diabetes when the goal is weight loss. Ozempic is dosed up to 2 mg for diabetes and is not interchangeable with Wegovy's 2.4 mg dose, even though both contain semaglutide. Insurers will flag off-label dose escalation and may reverse coverage mid-therapy.

Step-by-Step: How to Submit a PA That Gets Approved the First Time

A clean PA submission has six components. Missing any one of them is the most common reason for denial.

Step 1. Confirm the correct diagnosis code. For weight management, use E66.01 (morbid obesity due to excess calories) or E66.09 (other obesity). For cardiovascular risk reduction with Wegovy, use the appropriate CVD code alongside the obesity code. For diabetes, use E11.x with the most specific available modifier.

Step 2. Document BMI in the chart on the date of the PA request. Height and weight must appear in the clinical note tied to the visit, not only in a vital-signs flowsheet. Some electronic health records populate the PA form automatically; verify the date is current.

Step 3. Write a medical necessity letter. The letter should state the BMI, list the qualifying comorbidity if BMI is below 30, describe the prior diet and exercise attempts with dates, name the specific drug and dose requested, and cite the FDA label and the AACE guideline. One to two paragraphs is sufficient. Do not send a generic template; adjusters flag those quickly.

Step 4. Attach supporting lab work. For diabetes indications, attach the most recent HbA1c. For weight management, attach a metabolic panel, thyroid-stimulating hormone, and fasting lipids. These documents reduce follow-up requests and accelerate the review.

Step 5. Submit via the payer's preferred channel. Phone submissions are slower and create no paper trail. Use the payer's provider portal or fax the PA form with the supporting documents in a single transmission. Confirm receipt.

Step 6. Track the decision timeline. Standard commercial-plan timelines are 3 to 15 business days under federal and most state regulations. Urgent requests (where delay would seriously jeopardize health) must be resolved within 24 to 72 hours. Set a calendar reminder for day 14 to follow up if no decision has arrived.

What to Do If Your Prior Authorization Is Denied

Denials fall into four categories: wrong diagnosis code, missing documentation, step-therapy not completed, or formulary exclusion. Each requires a different response.

Wrong code or missing documentation denials are the easiest to fix. Resubmit with corrected codes and the missing attachments. Many denials at this stage overturn within 5 business days.

Step-therapy denials mean the plan requires a cheaper drug first (often orlistat, phentermine/topiramate, or bupropion/naltrexone). Document why the step drug is inappropriate for this patient: contraindications, a prior failed trial, or a clinical reason the prescriber can articulate in writing.

Formulary exclusion denials are the hardest. Some self-funded employer plans, and certain Medicare Part D plans, exclude all weight-loss drugs from their formulary as a benefit design choice rather than a clinical decision. In these cases, an appeal on medical necessity is unlikely to succeed, but requesting a formulary exception on the grounds of medical necessity (supported by the SELECT cardiovascular outcomes data [5]) has succeeded for some patients.

The formal appeal process runs: internal appeal (30-day window, 40 to 60% overturn rate with complete documentation), then external independent review (required under ACA for non-grandfathered plans), then state insurance commissioner complaint if external review is still adverse.

STEP-5 (N=304 to 104 weeks) showed that sustained semaglutide use maintained 15.2% weight loss at two years, while patients who switched to placebo regained approximately two-thirds of lost weight by week 120 [9]. Including that regain data in an appeal letter demonstrates that long-term therapy is medically necessary, not elective.

Real Costs: Wegovy, Zepbound, Ozempic, and Mounjaro Without Insurance

List prices shift with time and may differ by pharmacy, but the figures below reflect 2024 wholesale acquisition costs and are useful for counseling patients on what they face if PA is denied.

Wegovy (semaglutide 2.4 mg): Approximately $1,349 per month for four pens (one per week). The Novo Nordisk NovoCare savings program offers Wegovy for $0 per month to commercially insured patients whose plan covers it and whose household income meets program thresholds. Uninsured patients may qualify for $500 off per month through a separate offer, reducing the cost to roughly $850 at participating pharmacies.

Zepbound (tirzepatide): Approximately $1,060 per month. Eli Lilly's savings card brings the cost to $25 per month for commercially insured patients whose plan covers Zepbound, and $550 per month for those without coverage. Eli Lilly also offers Zepbound in single-dose vials through its LillyDirect pharmacy service at $349 to $499 per month for out-of-pocket patients, a significant reduction from the auto-injector pen list price.

Ozempic (semaglutide 1 mg/2 mg): Approximately $936 per month. The Novo Nordisk savings card for Ozempic can reduce cost to as little as $25 per month for eligible commercially insured patients.

Mounjaro (tirzepatide): Approximately $1,069 per month. The Eli Lilly savings card mirrors the Zepbound program: $25 per month for covered commercially insured patients, or up to $573 off the monthly list price for cash-pay patients.

Compounded semaglutide and tirzepatide were sold by 503A and 503B pharmacies during FDA shortage designations. The FDA removed tirzepatide from the shortage list in December 2024 and semaglutide in early 2025. Compounded versions of these drugs are no longer legally permissible under FDA policy once a shortage resolves, and insurers do not cover compounded GLP-1 products regardless of shortage status.

Medicare and Medicaid Coverage: Specific Rules

Medicare Part D historically excluded drugs for weight loss under the Part D statute. The Inflation Reduction Act did not change this blanket exclusion. A regulatory carve-out was made in 2024 for Wegovy specifically: CMS issued guidance allowing Part D plans to cover semaglutide 2.4 mg when prescribed for cardiovascular risk reduction in patients who meet the SELECT trial enrollment criteria (established cardiovascular disease plus BMI of 27 or higher). Plans are not required to cover it; they may elect to do so. Patients on Medicare should ask their Part D plan whether Wegovy appears on their 2025 formulary for the CVD indication, then request a PA under that indication if they qualify.

Medicaid coverage varies by state. As of early 2025, fewer than half of state Medicaid programs cover any GLP-1 for weight management, though most cover Ozempic and Mounjaro for type 2 diabetes. The National Academy for State Health Policy maintains a tracker that shows current state-by-state coverage status.

How Long Does Prior Authorization Take for Each Drug?

Timelines differ by payer category and submission method.

Commercial insurance plans must comply with the CMS Interoperability and Prior Authorization Final Rule (published January 2024), which requires most plans to respond to standard PA requests within 7 calendar days and to urgent requests within 72 hours, beginning in 2026. Many large commercial payers (including UnitedHealthcare, Anthem, Aetna, and Cigna) already operate close to this timeline for specialty drugs.

In practice, a complete PA submission for Wegovy or Zepbound at a commercial plan typically returns a decision in 5 to 10 business days. An incomplete submission, or one that triggers a peer-to-peer review request, adds 5 to 7 days. If the prescriber is not available for the peer-to-peer call within the plan's response window, the case may be auto-denied, which then requires a full appeal rather than a simple addendum.

Mounjaro PA for diabetes often resolves faster (3 to 7 business days) because the diabetes PA pathway is better established at most plans than the obesity pathway.

SURMOUNT-3 (N=579) enrolled patients who lost at least 5% of body weight through a 12-week lifestyle intervention before randomization and found that adding tirzepatide 15 mg produced an additional 18.4% weight reduction at 72 weeks [10]. This design, showing that pharmacotherapy works even after lifestyle optimization, is clinically relevant documentation for appeals arguing that diet and exercise alone are inadequate for a specific patient.

Peer-to-Peer Review: What Your Doctor Should Say

A peer-to-peer review is a phone call between the prescribing physician and a plan medical director. These calls typically last 10 to 20 minutes. The prescriber should have four things ready before the call begins.

First, the patient's current BMI and the qualifying comorbidity if BMI is below 30. Second, a brief summary of prior weight-loss attempts with approximate dates and outcomes. Third, the specific clinical reason the requested drug is preferred over step-therapy alternatives (for example, a patient with pancreatitis history cannot use certain options; a patient with MTC family history cannot use any GLP-1). Fourth, the relevant clinical trial data.

STEP-3 (N=611) showed that semaglutide 2.4 mg combined with intensive behavioral therapy produced 16.0% mean weight loss at 68 weeks, while intensive behavioral therapy plus placebo produced only 5.7% [11]. Quoting that difference in a peer-to-peer call demonstrates that the drug adds measurable benefit over the behavioral interventions the plan might otherwise require first.

The Endocrine Society's 2023 Obesity Pharmacotherapy Guideline states: "We recommend anti-obesity medications as an adjunct to lifestyle intervention for adults with obesity (BMI 30 kg/m² or higher) or overweight (BMI 27 to 29.9 kg/m²) with weight-related comorbidities when lifestyle intervention alone has not achieved the target weight loss." Quoting named guidelines by name in a peer-to-peer call carries weight with plan medical directors.

Switching Drugs After a Denial: Formulary Alternatives

If a specific GLP-1 is denied and an appeal is not feasible, the prescriber should review the plan's formulary tier structure for alternatives.

Some plans cover Ozempic (diabetes indication) but not Wegovy (weight management), even though both contain semaglutide. A patient with type 2 diabetes and obesity may qualify for Ozempic at a lower tier. This is not a clinical equivalent to Wegovy: the maximum dose of Ozempic is 2 mg weekly versus 2.4 mg weekly for Wegovy, and STEP-8 (N=338) showed that semaglutide 2.4 mg produced 15.8% weight loss versus 6.4% for liraglutide 3 mg at 68 weeks, confirming that dose and drug class both matter [12]. But for a patient who cannot access Wegovy, Ozempic at 2 mg with an off-label dose discussion is a clinical option the prescriber can raise.

Similarly, Mounjaro (tirzepatide for diabetes) may be covered when Zepbound (tirzepatide for obesity) is not, because the benefit design excludes weight-loss drugs as a category. The active ingredient is identical; the indication and NDC code differ. SURMOUNT-4 (N=670) showed that patients who withdrew tirzepatide after 36 weeks regained 14% of body weight by week 88, while those who continued lost an additional 5.5% [13]. Presenting that maintenance data supports the clinical case for continuing any form of tirzepatide once a patient is responding.